Abstract
Angiotensin-converting enzyme (ACE) inhibitors reduce morbidity, mortality, hospital admissions, and decline in physical function and exercise capacity in congestive heart failure (CHF) patients. These therapeutic effects are attributed primarily to beneficial cardiovascular actions of these drugs. However, it has been suggested that ACE inhibitorinduced positive effects may also be mediated by direct action on the skeletal muscle. In particular, two recently published observational studies documented that among hypertensive subjects free of CHF, treatment with ACE inhibitors was associated with better performance and muscular outcomes and genetic studies also support the hypothesis that the ACE system may be involved in physical performance and skeletal muscle function. Effects on the skeletal muscle are probably mediated by mechanical, metabolic, anti-inflammatory, nutritional, neurological and angiogenetic actions of these drugs. These studies may have major public health implications for older adults, as consequence of the fact that, in this population, gradual loss of muscle mass and muscle strength can play a key role in the onset and progression of disability. Therefore, if findings of observational studies will be later confirmed in randomized controlled trials, ACE inhibitors could represent an effective intervention to prevent physical decline in the elderly, leading to greater autonomy in this growing population.
Keywords: ACE inhibitors, skeletal muscle, disability, sarcopenia, older adults
Current Pharmaceutical Design
Title: Effects of ACE Inhibitors on Skeletal Muscle
Volume: 12 Issue: 16
Author(s): Graziano Ondera, Cecilia D. Vedova and Marco Pahorc
Affiliation:
Keywords: ACE inhibitors, skeletal muscle, disability, sarcopenia, older adults
Abstract: Angiotensin-converting enzyme (ACE) inhibitors reduce morbidity, mortality, hospital admissions, and decline in physical function and exercise capacity in congestive heart failure (CHF) patients. These therapeutic effects are attributed primarily to beneficial cardiovascular actions of these drugs. However, it has been suggested that ACE inhibitorinduced positive effects may also be mediated by direct action on the skeletal muscle. In particular, two recently published observational studies documented that among hypertensive subjects free of CHF, treatment with ACE inhibitors was associated with better performance and muscular outcomes and genetic studies also support the hypothesis that the ACE system may be involved in physical performance and skeletal muscle function. Effects on the skeletal muscle are probably mediated by mechanical, metabolic, anti-inflammatory, nutritional, neurological and angiogenetic actions of these drugs. These studies may have major public health implications for older adults, as consequence of the fact that, in this population, gradual loss of muscle mass and muscle strength can play a key role in the onset and progression of disability. Therefore, if findings of observational studies will be later confirmed in randomized controlled trials, ACE inhibitors could represent an effective intervention to prevent physical decline in the elderly, leading to greater autonomy in this growing population.
Export Options
About this article
Cite this article as:
Ondera Graziano, Vedova D. Cecilia and Pahorc Marco, Effects of ACE Inhibitors on Skeletal Muscle, Current Pharmaceutical Design 2006; 12 (16) . https://dx.doi.org/10.2174/138161206777442137
DOI https://dx.doi.org/10.2174/138161206777442137 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Clinical Value of Measuring the Renin/Aldosterone Levels: Optimising the Management of Uncontrolled/Resistant Hypertension
Current Vascular Pharmacology Telephone Follow-up of Older People After Hospital Admissions
Current Aging Science Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science Preclinical Testing of Drug-Induced Proarrhythmia: Value of Transgenic Models
Cardiovascular & Hematological Agents in Medicinal Chemistry Hydrogen Sulfide and Endothelial Dysfunction: Relationship with Nitric Oxide
Current Medicinal Chemistry Cardio-Renal-Anemia Syndrome: A Link Between Erythropoietin, Dimethylarginine and Homocysteine
Current Medicinal Chemistry FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews MicroRNAs in Platelet Biogenesis and Function: Implications in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Future Prospects in Anti-Platelet Therapy: A Review of Potential P2Y12 and Thrombin Receptor Antagonists
Recent Patents on Cardiovascular Drug Discovery New Insights into the Surgical Management of Tetralogy of Fallot: Physiological Fundamentals and Clinical Relevance
Current Pediatric Reviews Effects of High-Fat Diets from Different Sources on Serum and Thymus Lipid Profile: Study in an Experimental Model
Endocrine, Metabolic & Immune Disorders - Drug Targets ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Left Ventricular Non-compaction: From Recognition to Treatment
Current Pharmaceutical Design A Review of Fish Lectins
Current Protein & Peptide Science “Metabolically Healthy” Obesity: Fact or Threat?
Current Diabetes Reviews Targeting Peroxisome Proliferator-Activated Receptor Gamma for Generation of Antidiabetic Drug
Current Diabetes Reviews Exploring the Mechanism of Lingzhu San in Treating Febrile Seizures by Using Network Pharmacology
Combinatorial Chemistry & High Throughput Screening